Affordable Access

Publisher Website

Altered DNA methylation of CYP2E1 gene in schizophrenia patients with tardive dyskinesia.

Authors
  • Zhang, Ping1
  • Li, Yanli1
  • Wang, Kesheng2
  • Huang, Junchao1
  • Su, Brenda Bin3
  • Xu, Chun3
  • Wang, Zhiren1
  • Tan, Shuping1
  • Yang, Fude1
  • Tan, Yunlong4
  • 1 Beijing HuiLongGuan Hospital, Peking University HuiLongGuan Clinical Medical School, Beijing, 100096, China. , (China)
  • 2 Department of Family and Community Health, Robert C. Byrd Health Sciences Center, School of Nursing, West Virginia University, Morgantown, WV, 26506, USA. [email protected].
  • 3 Department of Health and Biomedical Sciences, College of Health Affairs, University of Texas Rio Grande Valle, Brownsville, TX, USA.
  • 4 Beijing HuiLongGuan Hospital, Peking University HuiLongGuan Clinical Medical School, Beijing, 100096, China. [email protected]. , (China)
Type
Published Article
Journal
BMC Medical Genomics
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Dec 09, 2022
Volume
15
Issue
1
Pages
253–253
Identifiers
DOI: 10.1186/s12920-022-01404-8
PMID: 36494682
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

About 20-30% of patients with schizophrenia develop tardive dyskinesia (TD). Oxidative stress is one potential causes of TD. CYP2E1 is considered as an oxidative stress-related gene, however, no study has been reported on the DNA methylation levels of the CYP2E1 in schizophrenia or TD. A total of 35 schizophrenia patients with TD, 35 schizophrenia patients without TD (NTD), and 35 health controls (HCs) were collected in Beijing, China. DNA was extracted from peripheral blood samples. The promoter methylation levels of CYP2E1 were detected using pyrosequencing. The generalized linear model (GLM) was used to examine the methylation levels of three CpG sites among three diagnostic groups (TD vs. NTD vs. HC). The average methylation levels were 8.8 ± 10.0, 14.5 ± 11.9 and 15.1 ± 11.3 in TD, NTD and HC groups, respectively. The F-test in GLM revealed overall differences in the average of methylation levels of three CpG sites among three diagnostic groups (p = 0.0227) and in the third CpG site (p = 0.0026). Furthermore, the TD group had lower average methylation levels than HC and NTD groups (p = 0.0115 and 0.0268, respectively). Specifically, TD group showed lower methylation levels in the third CpG site than HC and NTD groups (p = 0.0012 and 0.0072, respectively). Additionally, associations of the methylation levels with clinical features in the TD group were observed using Spearman correlation analysis. This study provides the first evidence of DNA methylation levels in the promoter of CYP2E1 gene associated with schizophrenia and TD. The abnormal DNA methylation might serve as a potential mechanism for TD. © 2022. The Author(s).

Report this publication

Statistics

Seen <100 times